The UI/MC SPORE Clinical Research Core (CRC) has as its primary goal to be the direct translational link between research projects and clinical research emanating from these projects.
The specific aims of the CRC are to: 1) coordinate and perform SPORE clinical trials protocols;2) manage SPORE observational epidemiology protocols and partner with the Molecular Epidemiology Resource (MER). The CRC provides a critical link between clinical research and the specific projects, cores, and developmental research. The CRC is co-directed by Thomas M. Habermann, MD, at the Mayo Clinic Cancer Center and Brian Link, MD, at the Holden Comprehensive Cancer Center. A key function of the CRC is to coordinate the development of clinical trials, assist in patient accrual, manage protocol amendments, report adverse events te appropriate agencies, and provide comprehensive quality control on clinical trial data. For the MER, the CRC consents newly diagnosed lymphoma patients, abstracts and enters clinical and epidemiologic data, and systematically follows all MER patients through death. Tumor tissue and peripheral bleed serum, cells, DNA, and RNA that are prospectively collected, stored and tracked by the Biospecimens Core are linked to the CRC database. This provides SPORE investigators integrated and centralized access for lymphoma research projects. During the last funding cycle, 10 therapeutic clinical trials were initiated or active, including 2 InterSPORE trials. Overall, we accrued 197 patients (331 since inception ofthe SPORE) to these SPORE clinical trials. Studies of novel agents such as the mTOR inhibitor everolimus and the farnesyltransferase inhibitor tipifarnib have been completed and published. For everolimus, a new trial has been approved for NCCTG and combination trials of tipifarnib proposed. We also completed two trials using the immunostimulatory agent CpG. CpG will now be moved fonward in SPORE Project 2. During the last funding cycle, 2461 patients were enrolled into the MER for a cumulative total of 4562 patients. Seminal publications in the area of lymphoma epidemiology were reported en statins, vitamin D deficiency, and serum free light chains. In the area of molecular epidemiology, genetic variation in genes in immune response, coagulation, NFKB, and complement pathways were linked to lymphoma risk er prognosis. Over 45 manuscripts were published from activities in this core in this last funding period.
|Makkouk, Amani; Weiner, George J (2015) Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge. Cancer Res 75:10-May|
|Xing, Xiaoming; Flotte, Thomas J; Law, Mark E et al. (2015) Expression of the chemokine receptor gene, CCR8, is associated With DUSP22 rearrangements in anaplastic large cell lymphoma. Appl Immunohistochem Mol Morphol 23:580-9|
|Workalemahu, Grefachew; Wang, Hong; Puan, Kia-Joo et al. (2014) Metabolic engineering of Salmonella vaccine bacteria to boost human V?2V?2 T cell immunity. J Immunol 193:708-21|
|Witzig, Thomas E; Maurer, Matthew J; Stenson, Mary J et al. (2014) Elevated serum monoclonal and polyclonal free light chains and interferon inducible protein-10 predicts inferior prognosis in untreated diffuse large B-cell lymphoma. Am J Hematol 89:417-22|
|Hu, Guangzhen; Lou, Zhenkun; Gupta, Mamta (2014) The long non-coding RNA GAS5 cooperates with the eukaryotic translation initiation factor 4E to regulate c-Myc translation. PLoS One 9:e107016|
|Cerhan, James R; Berndt, Sonja I; Vijai, Joseph et al. (2014) Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. Nat Genet 46:1233-8|
|Skibola, Christine F; Slager, Susan L; Berndt, Sonja I et al. (2014) Medical history, lifestyle, family history, and occupational risk factors for adult acute lymphocytic leukemia: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr 2014:125-9|
|Aschebrook-Kilfoy, Briseis; Cocco, Pierluigi; La Vecchia, Carlo et al. (2014) Medical history, lifestyle, family history, and occupational risk factors for mycosis fungoides and Sézary syndrome: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr 2014:98-105|
|Morton, Lindsay M; Slager, Susan L; Cerhan, James R et al. (2014) Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr 2014:130-44|
|Vajdic, Claire M; Landgren, Ola; McMaster, Mary L et al. (2014) Medical history, lifestyle, family history, and occupational risk factors for lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr 2014:87-97|
Showing the most recent 10 out of 229 publications